NEWS DETAIL

L’association T-DXd et sotorasib a montré une efficacité prometteuse dans les études précliniques sur le cancer du poumon non à petites cellules porteur de la mutation KRAS G12C – Oncodaily

L’association T-DXd et sotorasib a montré une efficacité prometteuse lors d’études précliniques sur le cancer du poumon non à petites cellules porteur de la mutation KRAS G12C.

Informations médicales

Contenu integral de l article

T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps. , ADCs, Antibody drug conjugates, HER2, HER2 expression, HER2 IHC, KRAS G12C, KRAS G12C-mutant NSCLC, KRAS inhibitor resistance, Lung cancer, NSCLC, OncoDaily Lung, Precision Oncology, preclinical oncology, Sotorasib, T-Dxd, targeted therapy, Thoracic Oncology, Trastuzumab deruxtecan, xenograft models

Produits lies a cet article

Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.

Questions frequentes

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Sotorasib – Acheter en ligne SOTOLDX Sotorasib 120 mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat